Age and gender disparities in the prevalence of lipitension

• Published in: European Heart Journal
• Main Authors: Grinshtein, Y U, Ruf, R, Shabalin, V
• Format: Article in Journal/Newspaper
• Language: English
• Published: Oxford University Press (OUP) 2021
• Subjects: Cardiology and Cardiovascular Medicine; Krasnoyarsk Krai
• Online Access: http://dx.doi.org/10.1093/eurheartj/ehab724.2318; https://academic.oup.com/eurheartj/article-pdf/42/Supplement_1/ehab724.2318/41055313/ehab724.2318.pdf

Abstract Introduction Lipitension is the presence of hypertension and dyslipidaemia in one person. It multiplies cardiovascular risk up to three-fold and therefore requires timely diagnosing and treatment. Purpose In the present study, we calculated the prevalence of lipitension and its disparities depending on gender and age. Methods We used the randomized sample of the ESSE-RF study that included 1603 urban and rural Krasnoyarsk Krai inhabitants aged 25–64. Each study participant signed informed consent and underwent the questionnaire, office blood pressure measurement, anthropometry, and biochemical blood analysis. Hypertension criteria were the measured systolic blood pressure at 140 mm Hg or higher, the measured diastolic blood pressure at 90 mm Hg or higher, or antihypertensive medications intake. Dyslipidaemia criteria were the total cholesterol level higher than 5.0 mmol/l, the low-density lipoprotein level higher than 3.0 mmol/l, the high-density lipoprotein level lower than 1.0 mmol/l in males and 1.2 mmol/l in females, or triglycerides level higher than 1.7 mmol/l. Results In 40.0% of people, we found a combination of at least one hypertension criterion and at least one dyslipidaemia criterion. The prevalence of lipitension significantly (chi-square for trend; p<0.001) increased from 10.7% in the 25–34 age group to 66.6% in the 55–64 age group. At a younger age, males had dyslipidaemia more frequently than females, while at 55–64, the prevalence of lipitension was higher in females. The details of age and gender disparities are shown in Table 1. Conclusion At least 40% of the general population and two-thirds of people older than 55 have lipitension and need a combined antihypertensive and lipid-lowering therapy. Funding Acknowledgement Type of funding sources: None. Table 1